Literature DB >> 35006619

Disrupted BRCA1-PALB2 interaction induces tumor immunosuppression and T-lymphocyte infiltration in HCC through cGAS-STING pathway.

Hui Ma1,2,3, Zhihua Kang2,3, Tzeh Keong Foo2,3, Zhiyuan Shen2,3, Bing Xia2,3.   

Abstract

BACKGROUND AND AIMS: BRCA1 (BRCA1 DNA repair associated) and PALB2 (partner and localizer of BRCA2) interact with each other to promote homologous recombination and DNA double-strand breaks repair. The disruption of this interaction has been reported to play a role in tumorigenesis. However, its precise function in HCC remains poorly understood. APPROACH AND
RESULTS: We demonstrated that mice with disrupted BRCA1-PALB2 interaction were more susceptible to HCC than wild-type mice. HCC tumors arising from these mice showed plenty of T-lymphocyte infiltration and a better response to programmed cell death 1 (PD-1) antibody treatment. Mechanistically, disruption of the BRCA1-PALB2 interaction causes persistent high level of DNA damage in HCC cells, leading to activation of the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) signaling pathway in both malignant hepatocytes and M1 macrophages in the tumor microenvironment. The activated cGAS-STING pathway induces programmed cell death 1 ligand 1 expression via the STING-interferon regulatory factor 3 (IRF3)-signal transducer and activator of transcription 1 pathway, causing immunosuppression to facilitate tumorigenesis and tumor progression. Meanwhile, M1 macrophages with an activated cGAS-STING pathway could recruit T lymphocytes through the STING-IRF3 pathway, leading to T-lymphocyte infiltration in tumors. After normalizing immune responses by PD-1 antibody treatment, the infiltrating T lymphocytes attack tumor cells rapidly and effectively.
CONCLUSIONS: This study reveals that persistent DNA damage caused by a defective BRCA pathway induces tumor immunosuppression and T-lymphocyte infiltration in HCC through the cGAS-STING pathway, providing insight into tumor immune microenvironment remodeling that may help improve HCC response to PD-1 antibody treatment.
© 2022 American Association for the Study of Liver Diseases.

Entities:  

Year:  2022        PMID: 35006619      PMCID: PMC9271123          DOI: 10.1002/hep.32335

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.298


  43 in total

1.  Genome-derived cytosolic DNA mediates type I interferon-dependent rejection of B cell lymphoma cells.

Authors:  Yu J Shen; Nina Le Bert; Anuja A Chitre; Christine Xing'Er Koo; Xing H Nga; Samantha S W Ho; Muznah Khatoo; Nikki Y Tan; Ken J Ishii; Stephan Gasser
Journal:  Cell Rep       Date:  2015-04-09       Impact factor: 9.423

Review 2.  Combination cancer immunotherapies tailored to the tumour microenvironment.

Authors:  Mark J Smyth; Shin Foong Ngiow; Antoni Ribas; Michele W L Teng
Journal:  Nat Rev Clin Oncol       Date:  2015-11-24       Impact factor: 66.675

3.  Male fertility defect associated with disrupted BRCA1-PALB2 interaction in mice.

Authors:  Srilatha Simhadri; Shaun Peterson; Dharm S Patel; Yanying Huo; Hong Cai; Christian Bowman-Colin; Shoreh Miller; Thomas Ludwig; Shridar Ganesan; Mantu Bhaumik; Samuel F Bunting; Maria Jasin; Bing Xia
Journal:  J Biol Chem       Date:  2014-07-11       Impact factor: 5.157

4.  Oral glutathione increases tissue glutathione in vivo.

Authors:  T Y Aw; G Wierzbicka; D P Jones
Journal:  Chem Biol Interact       Date:  1991       Impact factor: 5.192

5.  Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial.

Authors:  Richard S Finn; Baek-Yeol Ryoo; Philippe Merle; Masatoshi Kudo; Mohamed Bouattour; Ho Yeong Lim; Valeriy Breder; Julien Edeline; Yee Chao; Sadahisa Ogasawara; Thomas Yau; Marcelo Garrido; Stephen L Chan; Jennifer Knox; Bruno Daniele; Scot W Ebbinghaus; Erluo Chen; Abby B Siegel; Andrew X Zhu; Ann-Lii Cheng
Journal:  J Clin Oncol       Date:  2019-12-02       Impact factor: 44.544

Review 6.  Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.

Authors:  Kristian M Hargadon; Coleman E Johnson; Corey J Williams
Journal:  Int Immunopharmacol       Date:  2018-07-02       Impact factor: 4.932

Review 7.  PALB2 Variants: Protein Domains and Cancer Susceptibility.

Authors:  Thales C Nepomuceno; Marcelo A Carvalho; Amélie Rodrigue; Jacques Simard; Jean-Yves Masson; Alvaro N A Monteiro
Journal:  Trends Cancer       Date:  2020-11-01

8.  DNA damage induces reactive oxygen species generation through the H2AX-Nox1/Rac1 pathway.

Authors:  M A Kang; E-Y So; A L Simons; D R Spitz; T Ouchi
Journal:  Cell Death Dis       Date:  2012-01-12       Impact factor: 8.469

Review 9.  The cGAS-cGAMP-STING pathway connects DNA damage to inflammation, senescence, and cancer.

Authors:  Tuo Li; Zhijian J Chen
Journal:  J Exp Med       Date:  2018-04-05       Impact factor: 14.307

Review 10.  The abscopal effect: a sense of DNA damage is in the air.

Authors:  Timothy P Lippert; Roger A Greenberg
Journal:  J Clin Invest       Date:  2021-05-03       Impact factor: 19.456

View more
  2 in total

Review 1.  BRCA1-Dependent and Independent Recruitment of PALB2-BRCA2-RAD51 in the DNA Damage Response and Cancer.

Authors:  Tzeh Keong Foo; Bing Xia
Journal:  Cancer Res       Date:  2022-09-16       Impact factor: 13.312

2.  Prognostic Value of an Integrin-Based Signature in Hepatocellular Carcinoma and the Identification of Immunological Role of LIMS2.

Authors:  Fengning Ye; Hao Le; Fan He; Hao Tu; Dengfa Peng; Sini Ruan
Journal:  Dis Markers       Date:  2022-09-29       Impact factor: 3.464

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.